Multiple Gender Dimensions 63 3 Supplement 2. General and clinical characteristics of the study population Overall (n= 307) Mean ± SD Female (n= 127) Mean ± SD Intersex (n= 1) Mean ± SD Male (n= 179) Mean ± SD Age (years) 67.5 (8.3) 65.6 (8.6) 66.0 (NA) 68.8 (7.8) Age at diagnosis (years) 61.5 (9.4) 58.8 (9.7) 60.0 (NA) 63.5 (8.6) Disease duration (year) 6.1 (4.6) 6.9 (4.7) 6.0 (NA) 5.5 (4.4) SPDDS score (0 – 100) 34.3 (10.9) 36.0 (13.2) 25.0 (NA) 33.1 (8.7) PDQ-39 SI Score (0 – 100) 24.8 (12.5) 26.5 (12.3) 17.9 (NA) 23.7 (12.6) COVID-19 Stressor score (0-40) 2.5 (0.9) 2.5 (0.9) 2.4 (NA) 2.5 (0.9) Overall (n= 307) N (%) Female (n= 127) N (%) Intersex (n= 1) N (%) Male (n= 179) N (%) Medication use for PD (Yes) 294 (94) 121 (96) 1 (100) 172 (97) Education level None 0 (0) 0 (0) 0 (0) 0 (0) Primary education 6 (2.0) 2 (1.6) 0 (0) 4 (2.2) Secondary – prevocational 50 (16) 25 (20%) 0 (0) 25 (14) Secondary – higher 30 (9.8) 15 (12) 0 (0) 15 (8.4) Intermediate – vocational 54 (18) 22 (17) 0 (0) 32 (18) Higher - professional 164 (54) 62 (49) 1 (100) 101 (57) Other 1 (0.3) 0 (0) 0 (0) 1 (0.6) Comorbidities Heart diseases 62 (20) 21 (17) 0 (0) 41 (23) Lung diseases 29 (9.5) 11 (8.7) 0 (0) 18 (10) Musculoskeletal diseases 93 50 (40) 0 (0) 43 (24) Neuropsychiatric diseases 20 (6.6) 8 (6.3) 0 (0) 12 (6.7) Endocrine or Metabolic diseases 32 (10) 13 (10) 0 (0) 19 (11) Cancer 16 (5.2) 6 (4.8) 1 (100) 9 (5.1) None of the above 130 (43) 52 (41) 0 (0) 78 (44)
RkJQdWJsaXNoZXIy MTk4NDMw